Valuation: ProPhase Labs, Inc.

Market Cap 1.32M 1.15M 1.07M 994K 1.87M 125M 1.91M 12.78M 4.96M 61.51M 4.95M 4.84M 214M P/E 2024
-0.29x
P/E 2025 -0.26x
Enterprise Value 9.85M 8.62M 7.96M 7.42M 13.98M 931M 14.23M 95.43M 37.05M 459M 36.99M 36.17M 1.6B EV / Sales 2024
6.2x
EV / Sales 2025 2.44x
Free-Float
91.93%
Yield 2024 *
-
Yield 2025 -

Last Transcript: ProPhase Labs, Inc.

1 day-2.19%
1 week-16.36%
Current month-7.91%
1 month-20.35%
3 months+17.65%
6 months-79.70%
Current year-79.44%
1 week 0.09
Extreme 0.091
0.11
1 month 0.07
Extreme 0.0723
0.15
Current year 0.07
Extreme 0.068
0.47
1 year 0.07
Extreme 0.068
6.66
3 years 0.07
Extreme 0.068
75.9
5 years 0.07
Extreme 0.068
152.5
10 years 0.07
Extreme 0.068
160.4
Manager TitleAgeSince
Chief Executive Officer 67 19/06/2009
Director of Finance/CFO 66 06/08/2025
Director of Finance/CFO - -
Director TitleAgeSince
Chairman 67 19/06/2009
Director/Board Member 70 01/06/2009
Director/Board Member 56 20/06/2025
Date Insider Type Main position Quantity % Market Cap.
09/09/25Free

Chief Executive Officer

500,000 1.2036%
17/02/25Free

Chief Operating Officer

500,000 1.6737%
14/02/25Free

Director

100,000 0.3347%
Change 5-day change 1-year change 3-year change Capi.($)
-2.19%-16.36%-97.65%-99.87% 1.32M
+0.85%+15.89%+61.05%+459.12% 39B
+0.46%+8.96%+7.33%+16.75% 22.93B
-0.76%+5.05%-22.06%-42.37% 7.13B
+3.35%+8.65%+7.29%+87.19% 4.66B
-0.05%-1.53%+18.91%+49.25% 2.91B
-1.53%+17.53%-26.05%+1,045.30% 2.05B
+1.65%+25.72%+97.26%-10.27% 1.86B
-4.00%-4.53%+25.60%-24.92% 1.75B
+0.99%+1.92%+17.97%-4.30% 1.63B
Average -0.13%+12.46%+8.97%+147.59% 8.39B
Weighted average by Cap. +0.58%+13.95%+31.95%+245.61%

Financials

2024 2025
Net sales 6.77M 5.93M 5.47M 5.1M 9.61M 640M 9.79M 65.61M 25.47M 316M 25.43M 24.87M 1.1B 4.34M 3.8M 3.51M 3.27M 6.17M 411M 6.28M 42.11M 16.35M 203M 16.32M 15.96M 706M
Net income -53.36M -46.71M -43.12M -40.22M -75.78M -5.05B -77.14M -517M -201M -2.49B -200M -196M -8.67B -14.74M -12.9M -11.91M -11.11M -20.94M -1.39B -21.31M -143M -55.47M -688M -55.39M -54.15M -2.4B
Net Debt 23.9M 20.92M 19.31M 18.01M 33.93M 2.26B 34.54M 232M 89.91M 1.11B 89.77M 87.77M 3.88B 8.53M 7.46M 6.89M 6.43M 12.11M 806M 12.33M 82.65M 32.09M 398M 32.04M 31.32M 1.39B
Logo ProPhase Labs, Inc.
ProPhase Labs, Inc. is a biotech, genomics, and consumer products company. The Company is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. It develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The Company also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.
Employees
19
Date Price Change Volume
30/06/26 $0.0920 -2.19% 7,564
29/06/26 $0.0941 -5.94% 46,245
26/06/26 $0.1000 +9.77% 23,213
25/06/26 $0.0911 -4.61% 5,796
24/06/26 $0.0955 -13.18% 8,184

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PRPH Stock